中国医学前沿杂志（电子版）
中國醫學前沿雜誌（電子版）
중국의학전연잡지（전자판）
CHINESE JOURNAL OF THE FRONTIERS OF MEDICAL SCIENCE(ELECTRONIC VERSION)
2014年
7期
51-54
,共4页
康莱特%化疗%晚期非小细胞肺癌%生存期
康萊特%化療%晚期非小細胞肺癌%生存期
강래특%화료%만기비소세포폐암%생존기
Kanglaite%Chemotherapy%Advanced non-small cell lung cancer%Survival
目的：探讨康莱特辅助化疗对晚期非小细胞肺癌（NSCLC）患者生存期的影响。方法将126例确诊为晚期NSCLC患者随机分为观察组与对照组，每组各63例，对照组患者仅行化疗，观察组患者采用化疗联合康莱特治疗，比较两组患者的近期疗效并随访生存期情况。结果观察组治疗有效率为47.6%，对照组为20.6%，观察组患者1年生存率为68.3%，对照组为49.2%，观察组患者2年生存率为36.5%，对照组为14.3%，两组比较差异显著（P＜0.05），两组患者进行至少24个月的随访后，平均生存期分别为（689.4±164.1）天和（427.8±148.3）天（P＜0.05），观察组患者中位生存时间为568天，对照组为379天。结论康莱特联合辅助化疗可有效提升晚期NSCLC患者的近期疗效及2年生存率。
目的：探討康萊特輔助化療對晚期非小細胞肺癌（NSCLC）患者生存期的影響。方法將126例確診為晚期NSCLC患者隨機分為觀察組與對照組，每組各63例，對照組患者僅行化療，觀察組患者採用化療聯閤康萊特治療，比較兩組患者的近期療效併隨訪生存期情況。結果觀察組治療有效率為47.6%，對照組為20.6%，觀察組患者1年生存率為68.3%，對照組為49.2%，觀察組患者2年生存率為36.5%，對照組為14.3%，兩組比較差異顯著（P＜0.05），兩組患者進行至少24箇月的隨訪後，平均生存期分彆為（689.4±164.1）天和（427.8±148.3）天（P＜0.05），觀察組患者中位生存時間為568天，對照組為379天。結論康萊特聯閤輔助化療可有效提升晚期NSCLC患者的近期療效及2年生存率。
목적：탐토강래특보조화료대만기비소세포폐암（NSCLC）환자생존기적영향。방법장126례학진위만기NSCLC환자수궤분위관찰조여대조조，매조각63례，대조조환자부행화료，관찰조환자채용화료연합강래특치료，비교량조환자적근기료효병수방생존기정황。결과관찰조치료유효솔위47.6%，대조조위20.6%，관찰조환자1년생존솔위68.3%，대조조위49.2%，관찰조환자2년생존솔위36.5%，대조조위14.3%，량조비교차이현저（P＜0.05），량조환자진행지소24개월적수방후，평균생존기분별위（689.4±164.1）천화（427.8±148.3）천（P＜0.05），관찰조환자중위생존시간위568천，대조조위379천。결론강래특연합보조화료가유효제승만기NSCLC환자적근기료효급2년생존솔。
Objective To explore survival impact of Kanglaite adjuvant chemotherapy in advanced non-small cell lung cancer. Method 126 patients with advanced non-small cell cancer patients were randomly divided into observation group and control group, each group contained 63 cases, the control group treated with chemotherapy, and the observation group were treated with chemotherapy combined Kanglaite, recently efifcacy were observed and survival were followed-up. Result The effective rate was 47.6%in the observation group, and that was 20.6%in the control group, the 1-year survival rate was 68.3%and 49.2%in the observation group and the control group, the 2-year survival rate was 36.5%and 14.3%in the observation group and the control group, (P<0.05), the average survival period of observation group and control group was (689.4±164.1) days and (427.8±148.3) days with least 24 months followed-up, the median survival time was 568 days and 379 days in the observation group and the control group. Conclusion Kanglaite adjuvant chemotherapy can enhance the short-term efifcacy of non-small cell lung cance and two years survival rate.
